Thrive Wealth Management LLC Makes New $210,000 Investment in Charles River Laboratories International, Inc. (NYSE:CRL)

Thrive Wealth Management LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,000 shares of the medical research company’s stock, valued at approximately $210,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Charles River Laboratories International by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 5,935,727 shares of the medical research company’s stock valued at $1,685,568,000 after buying an additional 66,602 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Charles River Laboratories International by 35.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,506,293 shares of the medical research company’s stock worth $505,821,000 after acquiring an additional 653,790 shares during the last quarter. State Street Corp grew its holdings in Charles River Laboratories International by 0.9% during the 3rd quarter. State Street Corp now owns 2,031,141 shares of the medical research company’s stock worth $399,729,000 after acquiring an additional 19,084 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC increased its position in shares of Charles River Laboratories International by 0.7% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,628,363 shares of the medical research company’s stock valued at $328,636,000 after purchasing an additional 11,563 shares during the last quarter. Finally, Clearbridge Investments LLC raised its holdings in shares of Charles River Laboratories International by 2.6% in the 1st quarter. Clearbridge Investments LLC now owns 1,407,034 shares of the medical research company’s stock valued at $283,968,000 after purchasing an additional 36,176 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Bank of America boosted their target price on shares of Charles River Laboratories International from $235.00 to $245.00 and gave the stock a “buy” rating in a research note on Thursday, August 10th. JPMorgan Chase & Co. increased their price objective on Charles River Laboratories International from $225.00 to $250.00 and gave the company an “overweight” rating in a report on Thursday, August 10th. Citigroup cut Charles River Laboratories International from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $260.00 to $225.00 in a research note on Monday, July 10th. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Monday. Finally, TD Cowen started coverage on shares of Charles River Laboratories International in a research report on Wednesday, September 13th. They set a “market perform” rating and a $212.00 price objective for the company. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $244.55.

Insiders Place Their Bets

In other news, VP William D. Barbo sold 5,763 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $217.24, for a total transaction of $1,251,954.12. Following the completion of the sale, the vice president now owns 3,592 shares in the company, valued at $780,326.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, VP William D. Barbo sold 5,763 shares of Charles River Laboratories International stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $217.24, for a total value of $1,251,954.12. Following the transaction, the vice president now directly owns 3,592 shares in the company, valued at approximately $780,326.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Joseph W. Laplume sold 700 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $216.52, for a total transaction of $151,564.00. Following the transaction, the executive vice president now owns 24,983 shares of the company’s stock, valued at approximately $5,409,319.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,934 shares of company stock valued at $1,722,048. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Stock Up 1.3 %

CRL stock opened at $210.62 on Tuesday. The company has a market cap of $10.80 billion, a price-to-earnings ratio of 22.34, a price-to-earnings-growth ratio of 1.86 and a beta of 1.33. The company has a fifty day moving average price of $206.21 and a 200 day moving average price of $202.53. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.49 and a quick ratio of 1.21. Charles River Laboratories International, Inc. has a 12 month low of $181.22 and a 12 month high of $262.00.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 9th. The medical research company reported $2.69 EPS for the quarter, beating analysts’ consensus estimates of $2.63 by $0.06. Charles River Laboratories International had a net margin of 11.58% and a return on equity of 18.99%. The business had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.05 billion. During the same period in the prior year, the company earned $2.77 earnings per share. The business’s revenue was up 8.9% compared to the same quarter last year. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 10.49 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).